Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
Jiandong Huo, Audrey Le Bas, Reinis R. Ruza, Helen M. E. Duyvesteyn, Halina Mikolajek, Tomas Malinauskas, Tiong Kit Tan, Pramila Rijal, Maud Dumoux, Philip N. Ward, Jingshan Ren, Daming Zhou, Peter J. Harrison, Miriam Weckener, Daniel K. Clare, Vinod K. Vogirala, Julika Radecke, L. Moynié, Yuguang Zhao, Javier Gilbert‐Jaramillo, Michael L. Knight, Julia A. Tree, Karen R. Buttigieg, Naomi S. Coombes, Michael J. Elmore, Miles W. Carroll, Loïc Carrique, Pranav N. M. Shah, William James, Alain Townsend, David I. Stuart, Raymond J. Owens, James H. Naismith
Topics & Concepts
NeutralizationNeutralizing antibodyVirologyViral entryAntibodyTrimerCoronavirusChemistryEpitopeBinding sitePlasma protein bindingAvidityPhage displaySpike ProteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirusMolecular biologyBiologyCoronavirus disease 2019 (COVID-19)Viral replicationBiochemistryGeneticsMedicineDimerInfectious disease (medical specialty)Organic chemistryPathologyDiseaseSARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchViral gastroenteritis research and epidemiology